PRODUCT ACQUISITION OPPORTUNITY

FLOVASC drug was launched two years ago, and since it has achieved less than 1% of the market share. Its sales have been disappointing since its average performance can still be considered as low because, in patients with Cardiovascular complications and has a history of stroke, it can reduce death incidences at the rate of 1 out of 100 patients, typically 10% versus 9% incidence, which is still a lower rate—however, I advise the Client to pursue this deal because of the three years expected return.